Prior to weighting, region, presence of thrombocytopenia, AdvSM subtype, serum tryptase level ≥125 ng/ml, presence and number of mutated genes within SRSF2/ASXL1/RUNX1 gene panel, number of prior lines of therapy, and having received prior TKI therapy were unbalanced between the avapritinib and BAT cohorts (Table 2). This evidence concerns the gene ASXL1 and Thrombocytopenia.